DoubleDoubleDoubleDouble
  • About
  • What we do
  • News
  • Portfolio
  • Contact
  • About
  • What we do
  • News
  • Portfolio
  • Contact

Commercial-scale biomanufacturing of melatonin is here

  • 0 comments/
  • April 11, 2023

Conarium Bioworks is focused on producing melatonin, “one of the first mainstream consumer products replacing a synthetic compound with a compound that will be fully produced through biomanufacturing”.

This article from UC San Diego Today focuses on bioengineering professor (and Conarium Board member), Bernhard Palsson.

  • Under : Articles

Unibio announces $70M investment deal

  • 0 comments/
  • March 28, 2023

Unibio International PLC, the leading sustainable protein company, has announced that the Saudi Industrial Investment Group (“SIIG”) will invest approximately US$70 million (GBP 59 million) in Unibio.

The proceeds will be deployed to enable Unibio’s vision of feeding the world’s growing population in a sustainable way. Unibio will use the funds to roll-out new global production capacity, grow operating capabilities, and accelerate innovation and commercialisation.

More details on the Unibio website.

  • Under : Articles

Norfolk Plant Sciences featured in Forbes magazine

  • 0 comments/
  • March 24, 2023

“This Company’s GMO Will Help Feed The World, By Being Eaten”

Coverage of the launch of the Norfolk Healthy Produce anti-oxidant-rich purple tomato.

  • Under : Articles

Aida to enter BII Venture House

  • 0 comments/
  • March 1, 2023

Aida Oncology is part of the latest cohort of companies accepted on the Bioinnovation Institute’s Venture Lab programme.

The year-long programme will enable Aida to build the company and start to develop a product that will help to ensure that cancer patients are given the right drugs.

Details here.

More details on the BaseLaunch website.

  • Under : Articles

Biomanufacturing of melatonin is now possible

  • 0 comments/
  • February 28, 2023

This paper from Melatonin Research discusses novel techniques for biological synthesis of melatonin

  • Under : Articles

RhoVac AB (now known as Chosa Oncology AB) has completed the acquisition of Chosa ApS

  • 0 comments/
  • January 18, 2023

RhoVac AB has completed the acquisition of the Danish privately owned oncology company Chosa ApS (“Chosa”). As a result, a new board of directors of Chosa has taken office, and Peter Buhl Jensen replaces Lars Hedbys as CEO. More details on the Chosa website.

  • Under : Articles

How to Raise Money From a VC

  • 0 comments/
  • August 20, 2019

Should you raise venture capital for your startup? If so, how much?

Get some great advice in this article on Medium.

  • Under : Articles

Why Clinical Trial Design Can Make or Break Your Company

  • 0 comments/
  • August 20, 2019

In this fascinating interview with Labiotech Refresh Andrea Wallnöfer explains why good clinical trial design can be key to a biotech’s success.

  • Under : Articles

Processes kill innovation

  • 0 comments/
  • May 16, 2019

Read this interview with Double Founder Neil Goldsmith to learn more about how to detect startup-suitable talent and his current involvement with BaseLaunch.

  • Under : Articles

12
About Us

Double builds companies. Occasionally on our own, more usually with others.  Sometimes part of the founding team, sometimes working with established companies to help get things moving.

FIND US AT
  • The London BioScience Innovation Centre
    2 Royal College Street, London, NW1 0NH, United Kingdom
  • hello@248.bio
© Double Bioventures Ltd 2020. All Rights Reserved. Company registration number 11254142.